Finally, William Blair began coverage on shares of Immunic in a research note on Tuesday, March 25th. They issued an “outperform” rating for the company. One investment analyst has rated the ...

NEW YORK, April 10, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule ...

Fintel reports that on April 8, 2025, William Blair initiated coverage of Ocular Therapeutix (NasdaqGM:OCUL) with a Outperform recommendation. Analyst Price Forecast Suggests 195.25% Upside As of ...

On Tuesday, William Blair initiated coverage of Ocular Therapeutix (NASDAQ:OCUL), assigning the stock an Outperform rating and setting a fair value at $18 per share. The firm joins a broader analyst ...

On Tuesday, William Blair began coverage on Kalaris Therapeutics (NASDAQ:KLRS) with an Outperform rating and a fair value estimate of $21 per share. The stock, currently trading at $6.6 ...

In a report released today, Sharon Zackfia from William Blair maintained a Hold rating on El Pollo LoCo (LOCO – Research Report). The company’s shares closed today at $9.28. Discover ...

Prince William and Prince Harry’s former bodyguard, Graham Craker, has died at age 77. The beloved palace staffer, who was affectionally nicknamed “Crackers” by the young brothers ...

HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Immunic in a research report on Friday, February 21st. William Blair started coverage on shares of Immunic in ...

Fintel reports that on April 8, 2025, William Blair initiated coverage of Ocular Therapeutix (NasdaqGM:OCUL) with a Outperform recommendation. As of April 2, 2025, the average one-year price ...